A Phase 3 Open label, Randomized, Multicenter Study of Imprime PGG in Combination with Cetuximab (Erbitux) in Subjects with Recurrent or Progressive KRAS Wild Type Colorectal Cancer
|Effective start/end date||9/1/11 → 9/17/17|
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.